RVNC
Revance Therapeutics, Inc.
NASDAQ: RVNC · HEALTHCARE · BIOTECHNOLOGY
$3.65
+0.00% today
Updated 2026-10-29
Market cap
$381.02M
P/E ratio
—
P/S ratio
1.48x
EPS (TTM)
$-3.34
Dividend yield
—
52W range
$0 – $0
Volume
4.1M
Revance Therapeutics, Inc. (RVNC) Insider transactions
Net insider activity
Net selling (51,516 shares)
Buy transactions
46
Sell transactions
54
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-02-06 | WARE, OLIVIA C | Director | Sale | 15,000 | — | — |
| 2025-02-06 | SCHILKE, TOBIN | CFO | Sale | 103,555 | — | — |
| 2025-02-06 | SCHILKE, TOBIN | CFO | Buy | 20,883 | — | — |
| 2025-02-06 | RUSSELL, ANGUS C. | Director | Sale | 15,000 | — | — |
| 2025-02-06 | NOLET, CHRIS | Director | Sale | 15,000 | — | — |
| 2025-02-06 | MOXIE, DWIGHT | CLO & GC | Sale | 95,979 | — | — |
| 2025-02-06 | MOXIE, DWIGHT | CLO & GC | Buy | 18,125 | — | — |
| 2025-02-06 | KOLAJA, CAREY OCONNOR | Director | Sale | 15,000 | — | — |
| 2025-02-06 | JORDAN, ERICA | Chief Commercial Officer | Sale | 107,942 | — | — |
| 2025-02-06 | HOLLANDER, DAVID | CMO & Global Therapeutics Lead | Sale | 95,212 | — | — |
| 2025-02-06 | GANGOLLI, JULIAN S | Director | Sale | 15,000 | — | — |
| 2025-02-06 | FOLEY, MARK J | Director, President & CEO | Buy | 84,686 | — | — |
| 2025-02-06 | FOLEY, MARK J | Director, President & CEO | Sale | 27,933 | — | — |
| 2025-02-06 | CORIC, VLAD | Director | Sale | 15,000 | — | — |
| 2025-02-06 | BERAUD, JILL | Director | Sale | 15,000 | — | — |
| 2025-02-04 | WARE, OLIVIA C | Director | Sale | 16,675 | $3.65 | $60863.75 |
| 2025-02-04 | SCHILKE, TOBIN | CFO | Sale | 97,999 | $3.65 | $357696.35 |
| 2025-02-04 | RUSSELL, ANGUS C. | Director | Sale | 36,506 | $3.65 | $133246.90 |
| 2025-02-04 | NOLET, CHRIS | Director | Sale | 28,606 | $3.65 | $104411.90 |
| 2025-02-04 | MOXIE, DWIGHT | CLO & GC | Sale | 47,815 | $3.65 | $174524.75 |
| 2025-02-04 | KOLAJA, CAREY OCONNOR | Director | Sale | 16,561 | $3.65 | $60447.65 |
| 2025-02-04 | JORDAN, ERICA | Chief Commercial Officer | Sale | 6,922 | $3.65 | $25265.30 |
| 2025-02-04 | HOLLANDER, DAVID | CMO & Global Therapeutics Lead | Sale | 9,733 | $3.65 | $35525.45 |
| 2025-02-04 | GANGOLLI, JULIAN S | Director | Sale | 30,106 | $3.65 | $109886.90 |
| 2025-02-04 | FOLEY, MARK J | Director, President & CEO | Sale | 996,935 | $3.65 | $3.64M |
| 2025-02-04 | FOLEY, MARK J | Director, President & CEO | Sale | 110,913 | $3.65 | $404832.45 |
| 2025-02-04 | CORIC, VLAD | Director | Sale | 5,784 | $3.65 | $21111.60 |
| 2025-02-04 | BERAUD, JILL | Director | Sale | 28,606 | $3.65 | $104411.90 |
| 2025-02-03 | SCHILKE, TOBIN | CFO | Buy | 6,888 | — | — |
| 2025-02-03 | MOXIE, DWIGHT | CLO & GC | Buy | 5,979 | — | — |
| 2025-02-03 | FOLEY, MARK J | Director, CEO | Buy | 27,933 | — | — |
| 2024-12-31 | SCHILKE, TOBIN | CFO | Buy | 1,000 | $2.18 | $2184.50 |
| 2024-12-31 | FOLEY, MARK J | Director, CEO | Buy | 1,000 | $2.18 | $2184.50 |
| 2024-11-18 | HOLLANDER, DAVID | CMO & Global Therapeutics Lead | Sale | 3,908 | $4.17 | $16296.36 |
| 2024-06-30 | SCHILKE, TOBIN | CFO | Buy | 1,000 | $2.18 | $2184.50 |
| 2024-06-30 | FOLEY, MARK J | Director, CEO | Buy | 1,000 | $2.18 | $2184.50 |
| 2024-05-01 | WARE, OLIVIA C | Director | Buy | 23,458 | — | — |
| 2024-05-01 | WARE, OLIVIA C | Director | Buy | 15,000 | — | — |
| 2024-05-01 | RUSSELL, ANGUS C. | Director | Buy | 23,458 | — | — |
| 2024-05-01 | RUSSELL, ANGUS C. | Director | Buy | 15,000 | — | — |
| 2024-05-01 | NOLET, CHRIS | Director | Buy | 23,458 | — | — |
| 2024-05-01 | NOLET, CHRIS | Director | Buy | 15,000 | — | — |
| 2024-05-01 | KOLAJA, CAREY OCONNOR | Director | Buy | 23,458 | — | — |
| 2024-05-01 | KOLAJA, CAREY OCONNOR | Director | Buy | 15,000 | — | — |
| 2024-05-01 | GANGOLLI, JULIAN S | Director | Buy | 23,458 | — | — |
| 2024-05-01 | GANGOLLI, JULIAN S | Director | Buy | 15,000 | — | — |
| 2024-05-01 | CORIC, VLAD | Director | Buy | 23,458 | — | — |
| 2024-05-01 | CORIC, VLAD | Director | Buy | 15,000 | — | — |
| 2024-05-01 | BERAUD, JILL | Director | Buy | 23,458 | — | — |
| 2024-05-01 | BERAUD, JILL | Director | Buy | 15,000 | — | — |
| 2024-04-16 | JORDAN, ERICA | Chief Commercial Officer | Sale | 2,392 | $3.80 | $9096.30 |
| 2024-03-18 | SJUTS, DUSTIN S | President | Sale | 9,211 | $5.04 | $46446.47 |
| 2024-03-18 | SCHILKE, TOBIN | CFO | Sale | 9,361 | $5.04 | $47203.78 |
| 2024-03-18 | MOXIE, DWIGHT | CLO & GC | Sale | 8,125 | $5.04 | $40971.13 |
| 2024-03-15 | SJUTS, DUSTIN S | President | Sale | 2,967 | $5.31 | $15739.93 |
| 2024-03-15 | SCHILKE, TOBIN | CFO | Sale | 3,822 | $5.31 | $20275.71 |
| 2024-03-15 | MOXIE, DWIGHT | CLO & GC | Sale | 3,269 | $5.31 | $17342.04 |
| 2024-03-15 | FOLEY, MARK J | Director, CEO | Sale | 17,228 | $5.31 | $91394.54 |
| 2024-03-15 | FOLEY, MARK J | Director, CEO | Sale | 3,305 | $5.31 | $17533.02 |
| 2024-03-06 | FOLEY, MARK J | Director, CEO | Buy | 30,000 | $6.98 | $209400.00 |
| 2024-02-29 | SJUTS, DUSTIN S | President | Buy | 22,110 | — | — |
| 2024-02-29 | SCHILKE, TOBIN | CFO | Buy | 17,447 | — | — |
| 2024-02-29 | MOXIE, DWIGHT | CLO & GC | Buy | 15,143 | — | — |
| 2024-02-29 | FOLEY, MARK J | Director, CEO | Buy | 70,750 | — | — |
| 2024-01-31 | SCHILKE, TOBIN | CFO | Buy | 145,001 | — | — |
| 2024-01-31 | SCHILKE, TOBIN | CFO | Buy | 96,667 | — | — |
| 2024-01-31 | MOXIE, DWIGHT | SVP, GC & Secretary | Buy | 135,000 | — | — |
| 2024-01-31 | MOXIE, DWIGHT | SVP, GC & Secretary | Buy | 90,000 | — | — |
| 2024-01-31 | FOLEY, MARK J | Director, CEO | Buy | 1,070,001 | — | — |
| 2023-12-31 | SJUTS, DUSTIN S | President | Buy | 264 | $7.47 | $1972.08 |
| 2023-12-31 | SCHILKE, TOBIN | CFO | Buy | 434 | $7.47 | $3241.98 |
| 2023-12-31 | FOLEY, MARK J | Director, CEO | Buy | 264 | $7.47 | $1972.08 |
| 2023-12-15 | SJUTS, DUSTIN S | President | Sale | 4,712 | $8.08 | $38072.96 |
| 2023-09-06 | MOXIE, DWIGHT | SVP, GC & Secretary | Sale | 11,000 | $17.06 | $187704.00 |
| 2023-09-05 | MOXIE, DWIGHT | SVP, GC & Secretary | Sale | 23,853 | $17.81 | $424919.73 |
| 2023-08-11 | SJUTS, DUSTIN S | President | Buy | 22,620 | — | — |
| 2023-08-11 | SJUTS, DUSTIN S | President | Sale | 8,901 | $18.91 | $168317.91 |
| 2023-08-11 | SCHILKE, TOBIN | CFO | Buy | 22,620 | — | — |
| 2023-08-11 | SCHILKE, TOBIN | CFO | Sale | 11,215 | $18.91 | $212075.65 |
| 2023-08-11 | MOXIE, DWIGHT | SVP, GC & Secretary | Buy | 19,346 | — | — |
| 2023-08-11 | MOXIE, DWIGHT | SVP, GC & Secretary | Sale | 9,592 | $18.91 | $181384.72 |
| 2023-08-11 | FOLEY, MARK J | Director, CEO | Buy | 122,143 | — | — |
| 2023-08-11 | FOLEY, MARK J | Director, CEO | Sale | 48,064 | $18.91 | $908890.24 |
| 2023-08-03 | FOLEY, MARK J | Director, CEO | Sale | 26,279 | $22.57 | $593151.19 |
| 2023-07-03 | SCHILKE, TOBIN | CFO | Sale | 1,701 | $25.04 | $42593.04 |
| 2023-07-03 | FOLEY, MARK J | Director, CEO | Sale | 26,279 | $24.94 | $655332.56 |
| 2023-06-30 | SJUTS, DUSTIN S | President | Buy | 1,000 | $15.61 | $15606.00 |
| 2023-06-30 | SCHILKE, TOBIN | CFO | Buy | 769 | $15.61 | $12001.01 |
| 2023-06-30 | FOLEY, MARK J | Director, CEO | Buy | 1,000 | $15.61 | $15606.00 |
| 2023-06-15 | KOLAJA, CAREY OCONNOR | Director | Sale | 2,500 | — | — |
| 2023-06-15 | KOLAJA, CAREY OCONNOR | Director | Buy | 2,500 | $18.12 | $45300.00 |
| 2023-06-09 | SJUTS, DUSTIN S | President | Sale | 5,000 | $30.82 | $154096.00 |
| 2023-06-09 | FOLEY, MARK J | Director, CEO | Sale | 31,279 | $30.72 | $960928.41 |
| 2023-06-02 | SCHILKE, TOBIN | CFO | Sale | 500 | $31.00 | $15500.00 |
| 2023-06-01 | SCHILKE, TOBIN | CFO | Sale | 2,701 | $30.57 | $82569.57 |
| 2023-05-15 | SJUTS, DUSTIN S | President | Sale | 21,015 | $34.55 | $726003.10 |
| 2023-05-15 | SCHILKE, TOBIN | CFO | Sale | 21,401 | $34.55 | $739338.21 |
| 2023-05-15 | MOXIE, DWIGHT | SVP, GC & Secretary | Sale | 21,401 | $34.55 | $739338.21 |
| 2023-05-15 | FOLEY, MARK J | Director, CEO | Sale | 70,447 | $34.55 | $2.43M |
| 2023-05-03 | WARE, OLIVIA C | Director | Buy | 5,915 | — | — |
Frequently asked questions
Are RVNC insiders buying or selling?
Over the transactions on record, RVNC insiders have been net sellers, with about $14.82M in stock sold across 54 sales, against 12 open-market purchases.
Does insider selling at RVNC mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which RVNC insiders are selling the most?
Recent selling is concentrated in a few names. FOLEY, MARK J accounts for the largest share on record, with about $9.70M sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.